10-10/11 :: October/November 2010
nanotimes
Companies Facts
:
Within seconds, NanoFocus´ non-contact measurement systems deliver precise 3D data of technical surfaces in the micro and nanometer ranges. To always provide the best solutions to our customers, we internally design, develop and produce hardware and soft- ware for more than 15 years.
Now, NanoFocus goes inline too – same NanoFocus precision with over 1 million measure- ments per second to satisfy a broad range of industrial applications.
http://www.youtube.com/watch?v=uezGoh_oxss N 0-99
anoBio Corporation has received a $6M grant from the Bill & Melinda Gates Foundation to
support the development of a safe and effective intranasal vaccine for Respiratory Syncytial Virus (RSV). NanoBio is a privately held biopharmaceutical company focused on developing and commerciali- zing dermatological products, anti-infective treat- ments and intranasal vaccines derived from its paten- ted NanoStat™ technology platform. The Company’s lead product candidates are treatments for herpes labialis (licensed to GSK in the U.S. and Canada), onychomycosis, acne, cystic fibrosis and a broad platform of intranasal vaccines. The Company’s
enterprise applications. Development Kit units will be generally available from Kopin by January 2011 to software application developers and select Motorola enterprise and public safety customers. The develop- ment kits provide early access and experience with advanced hands-free mobile computing and commu- nication headsets capable of interfacing with existing legacy systems and software platforms.
http://www.kopin.com/golden-i/
29
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79